Researchers have been excited about the medication , a groundbreaking dual agonist showing promising outcomes in early trials for size reduction . It works by impacting both pathways : GLP-1 and GIP, that , when engaged , help control cravings and enhance calorie burn. Initial observations indicate substantial weight management and likely benefits